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2Abstract:
Objective: To estimate the impact of antiretroviral therapy (ART) on population-wide adult life
expectancy (LE).
Study design: A population-based open cohort study with repeated HIV status measurements and
registration of vital events in south-western Uganda (1991-2012).
Methods: Non-parametric survival analysis techniques are used for estimating trends in (i) the adult
LE of the general population (aged 15 and above), (ii) the adult LE by HIV status, and (iii) the adult LE
deficit associated with HIV. The LE deficit is estimated as the difference between overall LE and LE of
the HIV negative population. All estimates are disaggregated by sex.
Results: Between 1991-1993 and 2009-2012, population-wide adult LE increased from 39.3 (95%-CI:
35.9-42.8) to 56.1 years (95%-CI: 54.0-58.5) in women, and from 38.6 (95%-CI: 35.4-42.1) to 51.4
years (95%-CI: 49.2-53.7) in men. Most of the adult LE gains coincide with the introduction of ART in
2004; as evidenced by an increase in the adult LE of PLHIV between 2000-2002 and 2009-2012 of
22.9 and 20.0 years for women and men, respectively. Over the whole period of observation, the
adult LE deficit associated with HIV decreased from 16.1 (95%-CI: 12.7-19.8) to 6.0 years (95%-CI:
4.1-7.8) among women, and from 16.0 (95%-CI: 12.1-19.9) to 2.8 years (95%-CI: 1.2-4.6) among men.
Conclusion: Population-wide LE increased substantially, largely driven by reductions in HIV related
mortality. Women have gained more adult-life years than men since the introduction of ART, but the
burden of HIV in terms of the life-years lost is still larger for women than it is for men.
Key words: adult mortality, life expectancy, HIV, antiretroviral therapy (HIV), Uganda, sub-Saharan
Africa
3Introduction
Antiretroviral therapy (ART) is now widely available in sub-Saharan Africa and there is strong
evidence from clinical cohort studies in both developed and developing countries that ART has
increased the life expectancy (LE) of HIV infected people in treatment programs [1, 2]. Extrapolating
these estimates to all people living with HIV (PLHIV) is, however, problematic because facility data
lack information on those who never make contact with the health system, or, are lost to follow up.
Here, we use data from a demographic surveillance site in southwestern Uganda covering a period
ranging from the early 1990s to 2012. Repeated community-based testing for HIV ensures that the
HIV status is known for most adults, which allows us to estimate adult LE by HIV status and show
how these indices changed over time. Previous studies have used comparable data sources to
describe mortality trends in terms of mortality rates or the probabilities of surviving adulthood [3-7],
but detailed studies of population-level trends in (adult) LE are less common [8]. The appeal of LE as
an index of mortality is that it is more sensitive to the shift in the age distribution of deaths, and
therefore to the fact that ART prolongs the lives of PLHIV rather than eliminates AIDS deaths.
We describe the gains in adult life-years in terms of the adult LE of the population as a whole, and
the adult LE by HIV status. In addition, we quantify the remaining or residual burden of HIV on adult
mortality, and label this the adult LE deficit associated with HIV. A study from South Africa previously
used verbal autopsy data and cause-deleted life tables for estimating the LE deficit [8]; we measure
it as the difference between the LE of HIV negatives and the LE of the population as a whole [9].
Methods
Description of the Kyamulibwa General Population Cohort (GPC)
The GPC is a demographic surveillance site with around 23,000 current residents in 25 contiguous
villages located in the Kalungu district (formerly part of Masaka) in rural south-western Uganda. The
GPC covered 15 villages between 1989 and 1999 and has since been expanded with an additional 10
villages, including 4 small trading centres [10]. HIV prevalence in the study site was just under 7
percent prior to the rollout of ART  in 2004, and increased to 9 percent in 2010 [10].
Because mortality may be under-reported during the start-up phase of the GPC, we report results
for the period spanning 1991 to 2012. Data collection revolves around an annual census where
information is gathered on changes to household membership (births, deaths, in and out
migrations). The surveillance is complemented by village informants who record births and deaths in
their registers and report on a monthly basis to the project office.
HIV testing and uptake of results
Medical surveys with HIV testing have been conducted on an annual basis since the inception of the
GPC. Field workers contact all individuals aged 13 years and above who are resident for more than 3
months in the study villages, and obtain informed consent/assent before administering a study
questionnaire and HIV testing. Until 2012, blood samples were drawn at home and transported for
testing (two parallel ELISA tests) at the Medical Research Council (MRC) central laboratories in
Entebbe. Results were made available within approximately one month of testing and participants
could access their results at central counselling posts established in the study villages. Approximately
70% (range 61-89%) of the eligible residents that were contacted participated in the medical surveys
between 1991 and 2012 [10]. Between 1989 and 1999, the proportion of those tested who accepted
to receive their HIV results remained around 10%, despite an increase in the number of post-test
counselling posts in 1993. The uptake of results increased to 36% in 2000/2001 when home delivery
4of results was introduced [11]. Following the introduction of ART in 2004, the uptake of test results
increased to 46%, and to 56% in 2008 [12].  From 2012 onwards, rapid HIV testing with immediate
return of test results on the same day was introduced per national guidelines [13], and the survey
approach was also changed to invite participants for testing in a temporary hub in a central location
in each village. The proportion of those contacted and accepting to test has not changed much, but
the proportion of tested individuals who receive their result is now close to 99% (unpublished data).
Participants who are diagnosed with HIV infection are immediately referred for care.
ART services availability
ART became available in the study site in 2004. Most PLHIV choose to go to the MRC study clinic for
treatment, but ART is now also available in nearby public facilities. As per national guidelines, ART
eligible individuals have three adherence counselling visits and a medical examination prior to
treatment initiation. PLHIV are also required to identify a treatment adherence supporter. Following
ART initiation, patients are seen at the clinic after 2 weeks, 4 weeks and then at 3-monthly intervals,
or more frequently if there is a medical need. As for the other aspects of ART services provision, the
study clinic closely follows the guidelines of the Ministry of Health for determining treatment
eligibility (based on CD4 count thresholds), and in terms of treatment regimens. The study site may,
however, be atypical in the sense that the research clinic is better resourced than most public health
facilities in the area. This, for example, also facilitates the pro-active follow up of patients who miss
their scheduled appointments. This is not limited to HIV, but also includes patients with other
chronic conditions, including diabetes and hypertension. ART coverage in our study population has
always been relatively high, and probably somewhat higher than in the rest of Uganda.  For example,
based on ART initiation at CD4 counts ≤200, the estimated coverage in the GPC in 2008 was 69%
versus 53% for Uganda as a whole [12].
Life expectancy estimates
We estimate trends in three adult LE measures: (i) the adult LE of the general population, (ii) the
adult LE by HIV status (positive, negative and unknown), and (iii) the adult LE deficit associated with
HIV. All estimates are disaggregated by sex.
The adult LE is defined as the number of additional years that a 15-year old can expect to live under
the mortality rates that prevail in a particular year or period. It is a synthetic and age-standardized
measure of mortality, and accounts for the fact that ART prolongs the lives of PLHIV rather than
avoids AIDS associated deaths altogether. Using continuous-time survival analysis methods, the
adult LE is computed as the area under the Kaplan-Meier product-limit survivor curve between ages
15 and 100. As done elsewhere, we impose an upper age limit because the contribution of the years
lived by centenarians to the overall LE is often trivial but could be biased by age over-reporting [8].
Percentile-based confidence bounds around LE estimates are obtained via bootstrapping with 1,000
replications. Adult LE estimates are presented for groups of three calendar years because the
population is relatively small for single year estimates by sex and HIV status.
The adult LE deficit quantifies the effect of AIDS-associted mortality on the population-wide LE. It
treats the LE of HIV negatives as a benchmark of achievable LE and subtracts the observed LE for the
population as a whole. In other words, it is the average or per person number of adult life-years lost
to HIV. The adult LE deficit depends on the epidemic magnitude and maturity as well as the
mitigating effects of ART scale-up on HIV related mortality. Non-HIV mortality will moderate the LE
deficit as fewer life-years are lost to HIV in a population where the death rates from other causes are
high. Younger ages at HIV infection and death will widen the LE gap.
The age at infection and the presence of competing mortality risks are important considerations for
understanding gender differences in the adult LE trends and deficit because women have lower non-
5HIV related mortality in adulthood and they are usually infected at a younger age than men [14-16].
Elsewhere, we provide greater detail on factors that invalidate the interpretation of the difference
between the population-level LE and the LE of the HIV negatives as the LE deficit attributable to HIV
[9]. This includes correlated mortality risks (e.g., PLHIV have higher mortality rates from causes other
than HIV), and spill-over effects that may result from increased investments in HIV services, or, the
utilization of these services (e.g., PLHIV experience larger mortality reductions from other causes
because of their greater engagement with health services) [8, 17].
We complement our analyses of adult LE trends with an age decomposition of LE differences to
better understand the contribution of mortality differences in each age group to the overall LE
difference using a method described by Arriaga [18].  We conduct the age decomposition for two
quantities: (i) the overall LE gains that have been made compared to the pre-ART period, and (ii) the
current adult LE deficit.
HIV status imputation procedures
In order to allocate exposure time to the respective HIV status categories we classify time prior to
the first recorded HIV test as HIV status unknown. Failure to do so introduces downward bias in
mortality estimates because survivors would be the only ones contributing person-time prior to the
first test. Time following an HIV positive test remains positive until censoring or death. Any time
between two negative tests is counted as negative irrespective of the interval between tests.  The
time following the last negative test is considered negative for a duration corresponding to the
probability that 95% of their age group remains uninfected given the sex-specific HIV incidence rates
or death, whichever occurs first.
Results
In total, 27,925 adults aged 15 years and above have ever been resident in the GPC between 1991
and 2012 and included in the analysis (Table 1). A little over half (53.8%) of all adults are women and
they also contribute the majority of persons-years of exposure (52.4%). Because the HIV medical
survey with HIV testing is repeated each year, the HIV status information in the dataset is fairly
complete (83.2% of the person-years lived). The average person-year prevalence –defined as the HIV
positive person years divided by the HIV positive plus HIV negative person years– is 6.8%.
A total of 2,359 deaths occurred in the entire study period (1991-2012). Over half (57.3%) of the
deaths occurred after the age of 45 years.  The proportion of adults who died was highest among
PLHIV (29.5%), followed by those with HIV negative status (5.5%). Among people with unknown HIV
status, 3.1% died (Table 1).
Table 1 also gives a first indication of the changes in adult mortality that have taken place following
the introduction of ART services in the study site. Overall adult mortality rates have declined from
17.8 per 1,000 person-years (95%-CI: 16.9–18.8) in the pre-ART era to 11.9 per 1,000 (95%-CI: 11.2–
12.7) for the years following the introduction of ART. The most pronounced declines in mortality
have been registered among PLHIV where the death rates declined from 117.2 per 1,000 (95%-CI:
107.2–128.2) to 39.1 per 1,000 (95%-CI: 34.0–44.9). Detailed trends in mortality rates by HIV status
have been published elsewhere [3].
6Table 1: Study site characteristics, and death rates by age, sex, HIV status and period (Kyamulibwa
GPC, 1991-2012)
Variable Individualsa
Person years
of
observation
(PYOs)
Total
number of
deaths
Proportion
who died
(row %)
Adult mortality rates (per 1,000)
Pre–ART:
1991–2003
ART:
2004–2012
Rate  (95% CI) Rate  (95% CI)
All 27,925 159,638 2359 8.4 17.8 (16.9–18.8) 11.9 (11.2–12.7)
Males
15–19 yrs 7071 19,043 44 0.6 3.3  (2.3–4.7 ) 1.4  (0.8–2.4 )
20–24 yrs 4280 10,228 46 1.1 5.0  (3.5–7.3 ) 3.9  (2.5–6.1 )
25–34 yrs 3858 15,284 198 5.1 18.6 (15.8–21.8) 7.1  (5.4–9.3 )
35–44 yrs 2521 11,326 173 6.9 21.1 (17.5–25.5) 10.4 (8.1–13.3)
45+ yrs 2579 20,106 729 28.3 36.7 (33.1–40.7) 35.8 (32.3–39.7)
Females
15–19 yrs 7966 18,421 38 0.5 2.6  (1.8–3.9 ) 1.5  (0.9–2.5 )
20–24 yrs 5088 11,312 103 2.0 13.1 (10.4–16.4) 4.9  (3.4–7.2 )
25–34 yrs 4410 17,714 261 5.9 21.7 (18.8–25.1) 8.3  (6.6–10.4)
35–44 yrs 2775 12,727 145 5.2 15.0 (12.1–18.5) 8.4  (6.5–10.8)
45+ yrs 2969 23,477 622 20.9 30.8 (27.6–34.2) 22.8 (20.3–25.6)
HIV status
HIV negative 21,627 123,720 1182 5.5 10.2 (9.4–11.1) 8.9  (8.2–9.7 )
HIV positive 2279 9078 672 29.5 117.2(107.2–128.2) 39.1 (34.0–44.9)
HIV unknown 16,265 26,840 505 3.1 21.2 (18.9–23.8) 16.2 (14.1–18.5)
a Number of unique individuals observed in each age group or HIV status category. Individuals can contribute to more than
one category as they age or their HIV status changes during follow up.
The mortality rate reductions have also translated in important gains in adult LE, as illustrated in
Figure 1 (a-c). Detailed estimates along with their 95% confidence interval are presented in Appendix
1. Overall female LE increased from 39.3 years (95%-CI: 35.9-42.8) in 1991-1993 to 56.1 (95%-CI:
54.0-58.5) in 2009-2012, for a total gain of 16.8 years. The LE for men rose from 38.6 (95%-CI: 35.4-
42.1) to 51.4 years (95%-CI: 49.2-53.7) over the same period, for a total gain of 12.8 years. Among
women, 82.1% of these gains were achieved after 2000, and 38.1% after 2005. The corresponding
figures for men are 53.1% and 29.7%, respectively.
The adult LE of HIV negative women increased by 6.7 years between 1991-1993 and 2010-2012;
from 55.4 (95%-CI: 51.7-59.4) to 62.1 (95%-CI: 59.8-64.4). In contrast, the LE of HIV negative men
remained around 54 years: 54.6 years in 1991-1993 (95%-CI: 50.2-59.1) and 54.2 years in 2009-2012
(95%-CI: 51.9-56.8) (Figure 1, panel a).
The LE gain among PLHIV is pronounced for both sexes (Figure 1, panel b). Before the availability of
ART at the local health facility, the adult LE of HIV positive women and men hovered around or just
above 10 years. Between 2000-2002 and 2009-2012 the adult LE increased by 22.9 years for women
(from 13.0 (95%-CI: 10.9 - 15.4) to 35.9 years (95%-CI: 30.8 - 46.0)) and by 20.0 years for men (from
14.3 (95%-CI: 6.6 -20.6) to 34.3 (95%-CI: 18.3 - 47.3) years).  As was the case for the overall LE and
the LE for HIV negatives, HIV positive women have gained more life-years in the past decade than
HIV positive men, but the differences are smaller.
7The trend in the LE of adults with an unknown HIV status is similar to that of the population as a
whole, but LE estimates are on average a little lower (Figure 1, panel c). This suggests that PLHIV are
over-represented among those whose HIV status is unknown.
The adult LE deficit associated with HIV is presented in panel d of Figure 1. In the early 1990s, the
average number of life-years lost still amounted to 16.1 years (95%-CI: 12.7 - 19.8) for women and
16.0 years (95%-CI: 12.1 - 19.9) for men. By 2009-2012, the LE deficit had declined to 6.0 years (95%-
CI: 4.1 - 7.8) for women and to 2.8 years (95%-CI: 1.2 - 4.6) for men. Worth noting is that the LE
deficit started declining before introduction of treatment: by 2000-2002, the LE deficit had already
declined to 13.1 years (95%-CI: 10.3 – 15.9) among women and to 11.0 years (95%-CI: 8.2 - 14.2)
among men.
Figure 1 (a-d): Adult LE trends with 95%-confidence intervals by sex, period and HIV status
(Kyumalibwa GPC, 1991-2012)
a b
c d
The upper panel of Figure 2 illustrates the contributions of each age group to the adult LE gains that
have been made between 1991-2002 (the pre-ART period) and 2009-2012 (the most recent period
with data). The lowers panel depicts the age-group contributions to the LE deficit for 2009-2012. The
total LE gain that is decomposed in the upper panel amounts to 13.2 years for women and 8.8 year
for men, and illustrates that mortality reductions in women and men of reproductive age have
contributed most to the LE gains that have been made compared to the pre-ART years. The age
profile of these contributions to the overall adult LE is younger for women than for men, and that is
indeed what one would expect given their earlier age at infection [15]. The age-group contributions
to the current adult LE deficit associated with HIV (lower panel) are more evenly spread across the
adult age range, and that is the case for both women and men.
30
40
50
60
70
Ye
ar
s 
Li
ve
d 
be
tw
. 1
5 
an
d 
10
0
1991-'93 1994-'96 1997-'99 2000-'02 2003-'05 2006-'08 2009-'12
ART intro ART full
All Men All Women
Known HIV- men Known HIV- women
0
10
20
30
40
50
60
Ye
ar
s 
Li
ve
d 
be
tw
. 1
5 
an
d 
10
0
1991-'93 1994-'96 1997-'99 2000-'02 2003-'05 2006-'08 2009-'12
ART intro ART full
All Men All Women
HIV+ - men HIV+ - women
30
40
50
60
70
Ye
ar
s 
Li
ve
d 
be
tw
. 1
5 
an
d 
10
0
1991-'93 1994-'96 1997-'99 2000-'02 2003-'05 2006-'08 2009-'12
ART intro ART full
All Men All Women
HIV Unkn. - men HIV Unkn. - women
0
10
20
30
40
50
60
Ye
ar
s 
liv
ed
/lo
st
 b
et
w
. 1
5 
an
d 
10
0
1991-'93 1994-'96 1997-'99 2000-'02 2003-'05 2006-'08 2009-'12
ART intro ART full
Life years lived: Men Women
Life years lost to HIV: Men Women
88
Figure 2: age group contributions to the adult life-years gained between 1991-2001 and 2009-2012
(upper panel), and the adult LE deficit associated with HIV in 2009-2012 (lower panel),
Kyamulibwa GPC
Discussion
This population in rural Uganda has experienced large mortality reductions between 1991 and 2012,
amounting to an adult LE gain of 17 years for women and 13 years for men. The gains in adult LE are
largely driven by reductions in HIV related mortality; a finding that is supported by the LE trends
among HIV positive and HIV negative individuals: among PLHIV, the LE rose by 20 and 23 years
among men and women. Over the same period, the adult LE among HIV negatives improved by 7
years for women and did not change for men.
The large declines in HIV-associated mortality are also captured by the difference between the adult
LE of the HIV negative population and the LE of the population as a whole. In the early 1990s, this LE
deficit was still 16 years or more for both sexes, but has now shrunk to 6 years for women and 3
years for men. However, not all of the decline in the LE deficit is driven by the expansion of ART
programs and could also result from historical declines in HIV incidence [9]. Improvements in the
screening for, and management of opportunistic infections may have contributed to the declining
mortality among PLHIV prior to treatment availability, but the effect of earlier declines in HIV
incidence are probably more important. Mbulaiteye and colleagues reported a decline in HIV
incidence in the study population in the early 1990s [19],  which is expected to have caused a decline
in mortality around 10 years later [16]. This explanation is corroborated by our results because the
adult LE deficit started declining before the introduction of ART in 2004. Incidentally, differences in
the timing of the epidemic peak are also likely to explain the apparent discrepancy with a prior study
on adult LE trends following the expansion of ART programs in KwaZulu-Natal [8].  HIV prevalence is
three times as high in the South African study site, and one might therefore expect that the
expansion of treatment programs made a larger difference for adult mortality. However, Bor and
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colleagues estimated that adult LE increased by 11.3 years between 2004 and 2011, which is
comparable to the LE gains recorded in this study population, even though its HIV prevalence is
much lower. In the Ugandan case, declining mortality due to historical declines in HIV incidence
augments the LE gains achieved by the expansion of treatment. In South African the HIV epidemic
peaked later and adult LE would have continued to decline in the absence of treatment [8, 9].
Sex or gender differences in the life-years gained and lost offer a novel perspective on an ongoing
debate about equitable access to services [20]. The adult life-years gained by PLHIV is 3 years higher
for women than it is for men. As suggested elsewhere, differences in the engagement with health
services could explain some of the gender differences in the LE trends of PLHIV [21]. However, this
phenomenon is also related to variability in the age of infection and to differences in the background
mortality of men and women [9]. Women, for example, are usually infected at younger ages than
men [14-16], and have lower non-HIV mortality in adulthood. In the absence of treatment, a female
HIV infection and death will therefore incur a larger loss in LE. Conversely, preventing a female HIV
death will entail a larger gain in life-years.
Despite the larger gains in adult LE, women still have a larger LE deficit than men, which suggest that
the disproportionate burden of HIV on women persists. The matter is probably more complex than is
presented here, however, as the expansion of HIV services may produce spill-over effects with
possibly different repercussions for male and female mortality from causes that are unrelated to HIV
(e.g., via the strengthening of maternal health services provision) [17].
This study pertains to a relatively small population that has been under active surveillance for the
last 25 years, and for these reasons we cannot claim that it is representative for the country or even
rural areas within the country. However, with the exception of the community outreach with HIV
testing, the medical services provided to this population closely adhere to the national guidelines
and are indicative of their potential impact. The results from this study also provide an empirical
counterpoint for estimates that rely more heavily on modelling. The WHO, for example, reports
changes in Uganda’s national-level LE at age 15 between 1990-2012 of 3 years (from 46 to 49) and 6
years (from 42 to 48) for women and men, respectively [22]. Our results from south-western
Uganda are indicative of much larger mortality reductions and corresponding increases in adult LE
that are at least twice as high. Bor and colleagues noted equally large differences between a
demographic surveillance site in KwaZulu-Natal and national-level trends for South Africa [8], which
suggests that the WHO may have underestimated the LE gains following the expansion of treatment
programs in populations with generalized epidemics.
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Appendix 1: Life expectancy trends and 95% confidence intervals, by HIV status, sex and period
HIV status and sex Period Life expectancy (years) (95%CI)
All
Female 1991-1993 39.3 (35.9-42.8)
Female 1994-1996 40.9 (37.5-44.5)
Female 1997-1999 42.3 (39.1-46.2)
Female 2000-2002 44.0 (41.4-46.9)
Female 2003-2005 49.7 (47.0-52.6)
Female 2006-2008 53.1 (50.2-56.2)
Female 2009-2012 56.1 (54.0-58.5)
Male 1991-1993 38.6 (35.4-42.1)
Male 1994-1996 39.0 (35.6-42.6)
Male 1997-1999 44.6 (40.8-48.4)
Male 2000-2002 43.0 (40.4-45.8)
Male 2003-2005 47.6 (44.9-50.7)
Male 2006-2008 48.0 (45.4-50.6)
Male 2009-2012 51.4 (49.2-53.7)
HIV negative
Female 1991-1993 55.4 (51.7-59.4)
Female 1994-1996 56.1 (52.6-59.5)
Female 1997-1999 56.0 (51.9-60.8)
Female 2000-2002 57.1 (54.3-60.3)
Female 2003-2005 57.1 (54.3-60.1)
Female 2006-2008 59.8 (56.7-63.0)
Female 2009-2012 62.1 (59.8-64.4)
Male 1991-1993 54.6 (50.2-59.1)
Male 1994-1996 52.2 (48.2-56.4)
Male 1997-1999 55.0 (50.7-59.4)
Male 2000-2002 54.0 (50.7-57.3)
Male 2003-2005 54.9 (51.6-58.0)
Male 2006-2008 54.2 (51.3-57.2)
Male 2009-2012 54.2 (51.9-56.8)
HIV positive
Female 1991-1993 9.9  (1.8 -14.7)
Female 1994-1996 0.6  (0.4 -16.9)
Female 1997-1999 7.5  (0.7 -17.4)
Female 2000-2002 13.0 (10.9-15.4)
Female 2003-2005 19.3 (14.2-25.4)
Female 2006-2008 28.9 (22.4-37.3)
Female 2009-2012 35.9 (30.8-46.0)
Male 1991-1993 14.2 (6.0 -20.2)
Male 1994-1996 10.7 (4.3 -17.9)
Male 1997-1999 17.4 (8.1 -25.0)
Male 2000-2002 14.3 (6.6 -20.6)
Male 2003-2005 12.7 (5.1 -22.5)
Male 2006-2008 26.1 (17.1-34.0)
Male 2009-2012 34.3 (18.3-47.3)
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HIV status unknown
Female 1991-1993 30.1 (23.6-38.3)
Female 1994-1996 28.8 (22.1-37.7)
Female 1997-1999 27.6 (21.8-35.5)
Female 2000-2002 42.8 (36.3-50.0)
Female 2003-2005 44.1 (36.8-54.8)
Female 2006-2008 44.0 (36.9-52.7)
Female 2009-2012 44.7 (37.3-53.3)
Male 1991-1993 31.9 (27.0-39.4)
Male 1994-1996 40.0 (30.8-50.0)
Male 1997-1999 40.0 (30.7-50.9)
Male 2000-2002 48.7 (42.4-55.9)
Male 2003-2005 47.7 (41.8-55.0)
Male 2006-2008 44.2 (38.6-50.5)
Male 2009-2012 47.3 (42.2-52.6)
Life expectancy deficit  associated with HIV
Female 1991-1993 16.1 (12.7-19.8)
Female 1994-1996 15.2 (11.9-18.7)
Female 1997-1999 13.7 (9.9 -18.4)
Female 2000-2002 13.1 (10.3-15.9)
Female 2003-2005 7.4  (5.3 -9.7 )
Female 2006-2008 6.7  (4.1 -8.9 )
Female 2009-2012 6.0  (4.1 -7.8 )
Male 1991-1993 16.0 (12.1-19.9)
Male 1994-1996 13.2 (9.5 -16.8)
Male 1997-1999 10.4 (6.8 -14.1)
Male 2000-2002 11.0 (8.2 -14.2)
Male 2003-2005 7.2  (4.7 -10.0)
Male 2006-2008 6.2  (4.0 -8.7 )
Male 2009-2012 2.8  (1.2 -4.6 )
